Geron Corp
Open
SectorHealthcare
0.93 4.49
Overview
Share price change
24h
Min
0.88
Max
0.92
Income | -13M -17M |
|---|---|
Sales | 5.6M 57M |
EPS | -0.02 |
Profit margin | -29.019 |
Employees | 258 |
EBITDA | -16M -12M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +347.43% upside |
Next Earnings | 4 lis 2026 |
|---|
Market Cap | -82M 739M |
|---|---|
Previous open | -3.56 |
Previous close | 0.93 |
Geron Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Geron Corp Forecast
Price Target
By TipRanks
347.43% upside
12 Months Forecast
Average 4 USD 347.43%
High 5 USD
Low 3 USD
Based on 4 Wall Street analysts offering 12 month price targets forGeron Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Geron Corp
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.